Naschitz Brandes Amir has a proven track record of partnering with entrepreneurs, innovators, and visionaries who rely on the firm’s expertise to help them establish and realize their ventures’ business objectives, develop strategies for growth and maintain a competitive edge. We work with healthcare and life sciences companies at every stage of their growth cycle, from conception to commercial maturity and exit, as well as investors, banks, research institutions, healthcare providers, and other stakeholders in the medical ecosystem.


Our multidisciplinary team is made up of a diverse mix of attorneys, patent agents, and scientific advisors from variety of backgrounds, all of whom are well-attuned to the specific challenges that healthcare and life sciences companies face. Drawing on best-of-the-best capabilities, we help clients overcome these challenges and provide guidance with company formation and fundraising, patent applications, licensing and other commercial transactions and agreements, M&A transactions, capital markets, intellectual property strategy, privacy and data protection policies, employment issues, tax, and any necessary form of litigation.


We are proud to serve some of the most well-known and successful companies in the biotechnology, pharmaceutical, and healthcare sectors, as well as some of the fastest-growing startups at the intersection of life sciences and technology.

matching results
  • 10 September 2023

    Naschitz Brandes Amir Advises Bertelsmann on Investment in QuantHealth
  • 07 August 2023

    Nachitz Brandes Amir Hosts Meetup on Gender Lens Investing with IFIE and impact.51
  • 01 March 2022

    Naschitz Brandes Amir Advises MDClone on $63 Million Series C
  • 01 February 2022

    Naschitz Brandes Amir Advises CyberMDX on Acquisition by Forescout Technologies
  • 31 January 2022

    Naschitz Brandes Amir Lawyers Contribute Israel Chapter to Lexology Getting the Deal Through (GTDT) Digital Health 2022
  • 10 January 2022

    Naschitz Brandes Amir Advises MeMed on $93 Million Series E
  • 22 November 2021

    Naschitz Brandes Amir Advises Kamada on Acquisition of a Portfolio of Four FDA-Approved Commercial Products